



April 18, 2023

Dear Rett Syndrome Community,

Earlier this year Neurogene shared that the FDA cleared our Investigational New Drug (IND) application for NGN-401 gene therapy for the treatment of female children with Rett syndrome. NGN-401 is an investigational adeno-associated virus (AAV) gene therapy, using Neurogene's Expression Attenuation via Construct Tuning (EXACT) gene regulation technology. NGN-401 contains a full-length humanized MECP2 gene which is designed to express therapeutic levels of the MECP2 protein while avoiding overexpression.

Since that announcement, we have received requests from the community, seeking additional information about the clinical trial. The purpose of this letter is to provide additional details. Following, are frequently asked questions we've received:

What age range will be studied in this first clinical trial for NGN-401?

- This clinical trial will study the investigational gene therapy, NGN-401, in females with a confirmed diagnosis of typical Rett syndrome, aged 4-10 years old.

Will there be a clinical trial for a broader range of ages or for boys?

- Findings from this clinical trial will inform decisions regarding additional clinical trials or expansion of enrollment criteria.

How many participants will be included in the clinical trial, and will all participants receive NGN-401?

- This initial phase of the clinical trial will enroll 5 participants.
- As the clinical trial progresses, we anticipate enrolling additional participants.
- All participants will receive the investigational gene therapy, NGN-401.

Where will the clinical trial be conducted?

- We do not yet have the final details to share about the clinical trial site(s), as it takes time to prepare and finalize logistics with the sites.
- The clinical trial will be conducted at hospitals (clinical trial sites) in the US, and will be led by a team of medical experts who have a deep knowledge of gene therapy and experience caring for individuals with Rett syndrome.

Can families living outside of the United States enroll in the US clinical trial?

- Not at this time. We are early in the process of working with regulators to explore the opportunity for additional clinical trial sites outside the US. We will provide further information once it becomes available.

Will families be required to live near the clinical trial site?

- Families enrolled in the clinical trial will be required to live near the trial site for at least the first 3 months after dosing.
- Living near the clinical trial site is important to monitor safety and will be less disruptive to the daily lives of families, given the multiple in-person follow-up visits required throughout the course of the trial.

When will the clinical trial start enrolling participants?

- We expect enrollment to begin in the Summer/Fall of 2023.

Will clinical trial participants be allowed to be on trofinetide or in another clinical trial?

- Currently, for this clinical trial, participants who are taking, or have ever taken, trofinetide or who are in another clinical trial will not be eligible for enrollment.

When will Neurogene provide additional details about the clinical trial?

- Once the clinical trial is open for enrollment, we will send another communication to the community.
- Details will also be provided on www.clinicaltrials.gov, including the clinical trial site(s) and location(s).

Can families contact someone now to express their interest in being in the clinical trial?

- The clinical trial site details are not yet available, and there are no means to contact a site yet.
- The site(s) need to have the proper processes, training, resources and staffing in place before they can receive incoming interest from families.
- Neurogene, as the sponsor of the study, is unable to keep a list of interested families due to regulatory, legal, and compliance standards related to the conduct of a clinical trial.

How can Neurogene be contacted? Is Neurogene on social media?

Neurogene contact information is:

- By phone: +1-877-237-5020
- Patients and families can reach us at: patientinfo@neurogene.com
- Healthcare providers can reach us at: medicalinfo@neurogene.com
- Our website is: www.neurogene.com

We are on social media at the following channels:

- Neurogene Inc. Facebook page: <https://www.facebook.com/NeurogeneInc/>
- Neurogene Inc. Twitter handle: <https://twitter.com/NeurogeneInc/>
- Neurogene Inc. LinkedIn profile: <https://www.linkedin.com/company/NeurogeneInc>

We truly appreciate your patience as we work to begin enrollment in the clinical trial as soon as possible. We are also appreciative of the questions and interest we have received since our announcement of the IND clearance for NGN-401. We are committed to providing you with information as it becomes available. We will share future updates about the clinical trial with the Rett syndrome community and patient advocacy organizations, on our website, and through our social media channels.

Sincerely,

Kimberly Trant, RN, MBA
Executive Director, Patient Advocacy and Engagement